JP2021521794A5 - - Google Patents

Info

Publication number
JP2021521794A5
JP2021521794A5 JP2020557910A JP2020557910A JP2021521794A5 JP 2021521794 A5 JP2021521794 A5 JP 2021521794A5 JP 2020557910 A JP2020557910 A JP 2020557910A JP 2020557910 A JP2020557910 A JP 2020557910A JP 2021521794 A5 JP2021521794 A5 JP 2021521794A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
antisense oligomer
acceptable salt
exon
dystrophin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020557910A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021521794A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/028613 external-priority patent/WO2019209764A2/en
Publication of JP2021521794A publication Critical patent/JP2021521794A/ja
Publication of JP2021521794A5 publication Critical patent/JP2021521794A5/ja
Priority to JP2023202664A priority Critical patent/JP2024009344A/ja
Pending legal-status Critical Current

Links

JP2020557910A 2018-04-26 2019-04-23 筋ジストロフィーに対するエクソンスキッピングオリゴマーおよびオリゴマーコンジュゲート Pending JP2021521794A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023202664A JP2024009344A (ja) 2018-04-26 2023-11-30 筋ジストロフィーに対するエクソンスキッピングオリゴマーおよびオリゴマーコンジュゲート

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862663162P 2018-04-26 2018-04-26
US62/663,162 2018-04-26
PCT/US2019/028613 WO2019209764A2 (en) 2018-04-26 2019-04-23 Exon skipping oligomers and oligomer conjugates for muscular dystrophy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023202664A Division JP2024009344A (ja) 2018-04-26 2023-11-30 筋ジストロフィーに対するエクソンスキッピングオリゴマーおよびオリゴマーコンジュゲート

Publications (2)

Publication Number Publication Date
JP2021521794A JP2021521794A (ja) 2021-08-30
JP2021521794A5 true JP2021521794A5 (enExample) 2022-04-25

Family

ID=68295765

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020557910A Pending JP2021521794A (ja) 2018-04-26 2019-04-23 筋ジストロフィーに対するエクソンスキッピングオリゴマーおよびオリゴマーコンジュゲート
JP2023202664A Pending JP2024009344A (ja) 2018-04-26 2023-11-30 筋ジストロフィーに対するエクソンスキッピングオリゴマーおよびオリゴマーコンジュゲート

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023202664A Pending JP2024009344A (ja) 2018-04-26 2023-11-30 筋ジストロフィーに対するエクソンスキッピングオリゴマーおよびオリゴマーコンジュゲート

Country Status (4)

Country Link
US (2) US20210102205A1 (enExample)
EP (1) EP3784248A4 (enExample)
JP (2) JP2021521794A (enExample)
WO (1) WO2019209764A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
WO2020028832A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
EP3830259A4 (en) 2018-08-02 2022-05-04 Dyne Therapeutics, Inc. MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
CA3211038A1 (en) * 2021-02-12 2022-08-18 Oxford University Innovation Limited Cell-penetrating peptide conjugates and methods of their use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2627917T3 (es) * 2004-06-28 2017-08-01 The University Of Western Australia Oligonucleótidos no codificantes para la inducción de la omisión exónica y métodos de uso de los mismos
EP3133160B1 (en) * 2008-10-24 2018-12-12 Sarepta Therapeutics, Inc. Exon skipping compositions for dmd
TWI541024B (zh) * 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
AU2011367230B2 (en) * 2011-05-05 2017-08-10 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
WO2013030569A2 (en) * 2011-08-30 2013-03-07 Michael John Gait Peptides
CN106414739A (zh) * 2012-12-20 2017-02-15 萨雷普塔医疗公司 用于治疗肌营养不良症的改良的外显子跳跃组合物
EP3760720A1 (en) * 2013-03-14 2021-01-06 Sarepta Therapeutics, Inc. Exon skipping compositions for treating muscular dystrophy
HK1220154A1 (zh) * 2013-03-15 2017-04-28 Sarepta Therapeutics, Inc. 改进的用於治疗肌营养不良的组合物
MX2017011004A (es) * 2015-02-27 2018-02-09 Sarepta Therapeutics Inc Inclusion del exon2 inducida por antisentido en alfa-glucosidasa.acida.
JP2018530560A (ja) * 2015-10-09 2018-10-18 サレプタ セラピューティクス, インコーポレイテッド デュシェンヌ型筋ジストロフィーおよび関連障害の処置のための組成物および方法
MX384727B (es) * 2016-05-24 2025-03-14 Sarepta Therapeutics Inc Procesos para preparar oligómeros
KR20190024977A (ko) * 2016-06-30 2019-03-08 사렙타 쎄러퓨틱스 인코퍼레이티드 근육 이상증에 대한 엑손 스킵핑 올리고머

Similar Documents

Publication Publication Date Title
JP2020503010A5 (enExample)
JP2020503009A5 (enExample)
JP2021526017A5 (enExample)
JP2021503941A5 (enExample)
US10190117B2 (en) Double-stranded antisense nucleic acid with exon-skipping effect
JP2018518201A5 (enExample)
JP2025509438A5 (enExample)
EP3661563A1 (en) Biomimetic nanomaterials and uses thereof
JP2023511991A5 (enExample)
JP2018527013A5 (enExample)
JP2010505741A5 (enExample)
JP2018513682A5 (enExample)
JP2012505250A5 (enExample)
JP2012506703A5 (enExample)
JP2022536495A5 (enExample)
JP2015504650A5 (enExample)
TW201625274A (zh) 反義核酸
RU2015100198A (ru) Хиральный адъювант нуклеиновой кислоты
US10183977B2 (en) Stabilized STAT3 decoy oligonucleotides and uses therefor
JP2019529406A5 (enExample)
JP2009504803A5 (enExample)
JP2022533421A5 (enExample)
JP2013537404A5 (enExample)
JP2021506312A (ja) 鋳型指向性の核酸標的化合物
JP2020525502A5 (enExample)